



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

LETTER TO THE EDITOR

Leukocytoclastic vasculitis and COVID-19 vaccination



Vasculitis leucocitoclástica y vacunación COVID-19

Dear Editor,

We would like to share ideas on the publication "Leukocytoclastic vasculitis secondary to vaccination against SARS-CoV-2."¹ To summarize, Martn Guerra et al. stated that VLC secondary to the SARS-CoV-2 vaccine can be suspected from the first contact with the patient due to a history of vaccination and a common sign in a physical examination that any professional can do.¹ We agree that the COVID-19 vaccine can cause side effects, with leukocytoclastic vasculitis being one among them. The patient in this case developed leukocytoclastic vasculitis, according to the study. However, concluding the vaccine-interrelationship is still problematic. Because there is no information on the patient's health or immune status prior to immunization, it is impossible to rule out the potential of an underlying condition causing leukocytoclastic vasculitis. There is also the possibility of a concomitant medical condition causing leukocytoclastic vasculitis. Dengue fever, for example, may coexist with vaccination,² and dengue may be the cause of leukocytoclastic vasculitis.³

Funding

None declared.

Conflict of interest

None declared.

References

- Martín Guerra JM, Moreta Rodríguez M. Leukocytoclastic vasculitis secondary to vaccination against SARS-CoV-2. *Semergen*. 2022, <http://dx.doi.org/10.1016/j.semerg.2022.02.001>. S1138-3593(22)00047-8 [online ahead of print].
- Kebayoon A, Wiwanitkit V. Dengue after COVID-19 vaccination: possible and might be missed. *Clin Appl Thromb Hemost*. 2021;27, 10760296211047229.
- Jose A, Dhar M, Panda PK, Kishore S. Expanded dengue syndrome with small-medium-vessel vasculitis: a case report. *Int J Crit Illn Inj Sci*. 2021;11:39–42.

P. Sookaromdee^{a,*}, V. Wiwanitkit^b

^a *Private Academic Consultant, Bangkok, Thailand*

^b *Adjunct Professor, Joseph Ayobabalola University, Ikeji-Arakeji, Nigeria*

* Corresponding author.

E-mail address: pathumsook@gmail.com (P. Sookaromdee).